Back to top
more

Encompass Health (EHC)

(Delayed Data from NYSE)

$123.81 USD

123.81
465,272

-0.85 (-0.68%)

Updated Sep 16, 2025 03:59 PM ET

After-Market: $123.76 -0.05 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (63 out of 245)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why Encompass Health (EHC) is a Strong Growth Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Aveanna Healthcare Holdings Inc. (AVAH) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Aveanna (AVAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Encompass Health Opens New Rehabilitation Hospital in The Villages

by Zacks Equity Research

EHC expands in Central Florida with a new 50-bed rehab hospital in The Villages, boosting its growth and patient care network.

Kaibalya Pravo Dey headshot

Encompass Health Flexes Its Muscle: Margins Widen as Volumes Climb

by Kaibalya Pravo Dey

EHC's rising patient volumes, expanding footprint and tighter cost controls are fueling margin growth and a strong 2025 outlook.

Zacks Equity Research

Encompass Health Corporation (EHC) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

Encompass Health (EHC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Encompass Health (EHC) Up 8.6% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Encompass Health (EHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Is it Time to Hold on to Community Health Systems Stock?

by Zacks Equity Research

CYH benefits from rising occupancy, higher revenue per admission, and business streamlining, supporting its case as a stock to retain in your portfolio.

Zacks Equity Research

Why Encompass Health (EHC) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Is Encompass Health (EHC) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Encompass Health (EHC) and Idexx Laboratories (IDXX) have performed compared to their sector so far this year.

Zacks Equity Research

Why Encompass Health (EHC) is a Top Value Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Aveanna Healthcare Holdings Inc. (AVAH) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

Aveanna (AVAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

NVNO's Shares Decline on Unfavorable FDA Review Outcome for VenoValve

by Zacks Equity Research

enVVeno Medical shares plunge after the FDA rejects its VenoValve PMA, citing insufficient trial data and safety concerns tied to the surgical procedure.

Zacks Equity Research

NVCR Stock Slips Despite PMA Application to Treat Pancreatic Cancer

by Zacks Equity Research

NovoCure submits a PMA to the FDA for TTFields therapy in pancreatic cancer, aiming to expand its oncology reach.

Zacks Equity Research

Encompass Health Corporation (EHC) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Encompass Health (EHC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Here's Why Encompass Health (EHC) is a Strong Momentum Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Here's Why Encompass Health (EHC) is a Strong Growth Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Encompass Health Q2 Earnings Beat Estimates, Stock Up 7.4%

by Zacks Equity Research

EHC posts strong Q2 with higher EPS, revenue growth, and a raised 2025 outlook, along with shares gaining 7.4%.

Zacks Equity Research

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Is Encompass Health (EHC) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Encompass Health (EHC) and Johnson & Johnson (JNJ) have performed compared to their sector so far this year.

Zacks Equity Research

Encompass Health (EHC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Encompass Health (EHC) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Encompass Health (EHC) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Encompass Health (EHC) delivered earnings and revenue surprises of +16.67% and +2.29%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Can Phosphate Binders Drive DaVita Stock Before Q2 Earnings?

by Zacks Equity Research

DVA rides early momentum from phosphate binders ahead of second-quarter 2025 earnings, but PD supply issues may cloud growth.

Zacks Equity Research

Option Care (OPCH) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Option Care (OPCH) delivered earnings and revenue surprises of +2.50% and +4.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

DaVita HealthCare (DVA) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

DaVita HealthCare (DVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Encompass Health (EHC) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Encompass Health (EHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.